BI 51013

Drug Profile

BI 51013

Alternative Names: Anti-alpha-beta-TCR monoclonal antibody BMA-031; Anti-T cell receptor alphabeta monoclonal antibody BMA031; Anti-TCR-alphabeta monoclonal antibody BMA031; Behring Monoclonal Antibody; BMA 031; Monoclonal antibody BMA031

Latest Information Update: 26 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aventis Behring LLC
  • Developer Aventis Behring
  • Class Monoclonal antibodies
  • Mechanism of Action T-cell receptor antigen alpha-beta antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Graft-versus-host disease; Renal transplant rejection; Transplant rejection

Most Recent Events

  • 25 Jan 2017 Discontinued - Phase-II for Graft-versus-host disease in Germany, USA (unspecified route)
  • 25 Jan 2017 Discontinued - Phase-III for Renal transplant rejection in USA, Germany (IV)
  • 25 Jan 2017 Discontinued - Preclinical for Transplant rejection in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top